~~Table~~UNITED ofSTATES SECURITIES ~~Contents~~AND EXCHANGE COMMISSION

~~UNITED~~WASHINGTON, ~~STATES SECURITIES~~D.C. ~~AND EXCHANGE COMMISSION~~20549

~~WASHINGTON,~~FORM ~~D.C. 20549~~8-K

~~FORM~~CURRENT ~~8-K~~REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

~~CURRENT REPORT~~Date ~~PURSUANT~~of TOReport ~~SECTION 13 OR 15~~(d)Date OFof ~~THE SECURITIES~~earliest ~~EXCHANGE~~event ~~ACT~~reported) OFApril 7, ~~1934~~ 2010

VION PHARMACEUTICALS, INC.

~~Date of Report~~ (~~Date~~Exact Name of ~~earliest~~Registrant ~~event~~as ~~reported)~~Specified ~~March~~in ~~22,~~its ~~2010~~ Charter)

VION PHARMACEUTICALS, INC.


Delaware	000-26534	13-3671221

(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4 Science Park, New Haven, CT		06511

(Address of Principal Executive Offices)		(Zip Code)

~~(Exact Name of~~ Registrant’s astelephone ~~Specified~~number, inincluding ~~its~~area ~~Charter~~code: (203) 498-4210

Not Applicable

Delaware		000-26534		13-3671221
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

(Former Name or Former Address, if Changed Since Last Report)

4 Science Park, New Haven, CT		06511
(Address of Principal Executive Offices)		(Zip Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

~~Registrant’s~~o Written ~~telephone~~communications ~~number,~~pursuant ~~including~~to ~~area~~Rule 425 ~~code:~~under the Securities Act (~~203~~17 CFR 230.425) ~~498-4210~~

~~Not~~o Soliciting ~~Applicable~~material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

~~(Former~~o Pre-commencement ~~Name~~communications orpursuant ~~Former~~to ~~Address,~~Rule 14d-2(b) ifunder ~~Changed~~the ~~Since~~Exchange ~~Last~~Act ~~Report~~(17 CFR 240.14d-2(b))

~~Check the appropriate box below if the Form 8~~o Pre-Kcommencement ~~filing~~communications ispursuant ~~intended~~ to ~~simultaneously~~Rule 13e-4(c) ~~satisfy the filing obligation of the registrant~~ under ~~any of~~ the ~~following~~Exchange ~~provisions~~Act (~~see~~17 ~~General Instruction~~CFR A240.~~2. below~~13e-4(c):)

~~o Written communications pursuant to Rule~~Item ~~425~~1.03 ~~under~~Bankruptcy ~~the~~or ~~Securities Act (17 CFR 230.425)~~Receivership

o As ~~Soliciting~~previously ~~material~~disclosed, on December 17, 2009, Vion Pharmaceuticals, Inc. (“Vion”), a Delaware corporation filed a voluntary petition seeking relief pursuant to ~~Rule~~Chapter ~~14a-12~~11 ~~under~~of Title 11 of the United ~~Exchange~~States ~~Act~~Code (17“Chapter 11”) ~~CFR~~in ~~240~~the United States Bankruptcy Court for the District of Delaware (the “Court”) (Case No.~~14a~~ 09-1214429 (CSS)).

o On ~~Pre-commencement~~February 11, ~~communications~~2010 ~~pursuant~~Vion tofiled ~~Rule~~with the Court a Chapter ~~14d-2~~11 Plan of Liquidation (bas amended, the “Plan”) ~~under~~and a related disclosure statement. On April 7, 2010, the Court ~~Exchange~~entered ~~Act~~an order (17the ~~CFR~~“Confirmation Order”) ~~240~~confirming the Plan.~~14d-2~~ The Plan became effective on April 8, 2010 (bthe “Effective Date”)). A copy of the Confirmation Order confirming the Plan is attached hereto as Exhibit 99.1.

oSummary ~~Pre-commencement~~of ~~communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR~~Plan ~~240.13e-4(c))~~

~~TABLE~~ The OFfollowing ~~CONTENTS~~is a summary of the material terms of the Plan, as confirmed by the Court. The summary is qualified in its entirety by reference to the Plan. Capitalized terms used but not defined herein have the meanings given to them in the Plan.

~~Item~~ Pursuant ~~8.01~~to ~~Other~~the ~~Events~~Plan, ~~Item~~on 9the Effective Date, all of Vion’s assets and liabilities, excluding certain licenses and drug applications that are being retained by Vion, are to be transferred to the Vion Liquidating Trust for the purpose, among other things, of making distributions to the Holders of Allowed Claims, pursuing Causes of Action, and liquidating the Estate.01 ~~Financial~~The ~~Statements~~Plan provides for the appointment of a Liquidating Trustee for the purpose of liquidating and ~~Exhibits~~distributing ~~SIGNATURES~~all ~~EXHIBIT~~of Vion’s ~~INDEX~~remaining ~~EX-99~~assets.1

~~Table~~ Other ofthan ~~Contents~~Administrative Claims and Priority Tax Claims, which will be paid in full (or the amount awarded by the Court) as soon as practicable under the Plan, the potential claims and interests in Vion are divided into four classes under the Plan:

~~Item 8~~• Class 1 consists of Priority Claims, the holders of which are entitled to receive payment in full, in cash, without interest, in relative order of priority pursuant to Bankruptcy Code § 507, as soon as practicable after the later of the Effective Date or within ten days after the date on which such Claim becomes an Allowed Claim.01 ~~Other~~• ~~Events~~Class 2 consists of Secured Claims, the holders of which are entitled to, at the option of the Liquidating Trustee, (i) have such Claim reinstated and rendered unimpaired in accordance with Bankruptcy Code § 1124(2); or (ii) receive Cash or the collateral securing its Claim, in full and complete satisfaction of such Claim, on the later of the Initial Distribution Date under the Plan and the date such Claim becomes an Allowed Claim, or as soon thereafter as is practicable. • Class 3 consists of General Unsecured Claims, including holders of Vion’s convertible debt, the holders of which are entitled to receive their Pro Rata share of Distributable Cash, until paid in full. In the event the Claims are paid in full, holders of Class 3 Claims are entitled to interest from the Petition Date through the Effective Date.

As• ~~previously~~Class ~~disclosed,~~4 onconsists ~~December 17, 2009, Vion Pharmaceuticals, Inc. (the “Registrant”) filed a voluntary petition seeking relief pursuant to chapter 11~~ of ~~Title~~Interests 11 of the United States Code (“Chapter 11”) in the United States Bankruptcy Court for the District of Delaware (the “Court”) (Case No. 09-14429) (CSS). On February 11, 2010 the Registrant filed with the Court a Chapter 11 Plan of Liquidation (“Plan”) and aInterest ~~related~~Related ~~disclosure statement (“Disclosure Statement”) . On March 1~~Claims, ~~2010,~~holders ~~the Court entered an order (i) approving the adequacy~~ of ~~information~~which inare ~~the Disclosure~~not ~~Statement and (ii) approving the Registrant’s procedures for soliciting votes on the Plan and authorizing the Registrant to send the Disclosure Statement, the Plan and ballots to creditors~~ entitled to ~~vote~~receive onany ~~the~~distribution Plan. The deadline for voting on the Plan is March 30, 2010 at 4:00 P.M. and the hearing on confirmation of the Plan is scheduled for April 6, 2010. All information contained in the Disclosure Statement is subject to change, whether as a result of amendments to the Plan, actions of third parties or ~~otherwise. Assuming~~dividend ~~that the hearing~~ on ~~confirmation~~account of ~~the~~such Plan is held on or before the scheduled date, and that the Plan is so confirmed at the scheduled hearing and goes effective by its terms, the Registrant anticipates that it will then no longer be a reporting company under the Securities Exchange Act of 1934, as amended, and accordingly, the Registrant does not intend to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2009Interest.

OnThe ~~March 22,~~listing ~~2010,~~of a class above does not necessarily mean that there are any claims or interests within such class existing as of the ~~Registrant~~Effective ~~filed~~Date. ~~its~~The ~~unaudited~~Disbursing ~~monthly~~Agent ~~operating~~shall ~~report~~make ~~for~~initial distributions under the ~~month~~Plan on account of Claims Allowed before the Effective Date as soon as ~~February 2010~~practicable (on or after the ~~“Monthly~~Effective ~~Operating~~Date, ~~Report”)~~except ~~with~~as otherwise agreed to by the ~~Court.~~Trust AOversight Committee ~~copy~~or by order of the ~~Monthly Operating~~Bankruptcy ~~Report~~Court, isand ~~contained~~thereafter as described in the ~~attached Exhibit 99~~Plan.1.

~~This~~Share ~~Current Report on Form 8-K is not intended to be, nor should it be construed as, a~~Information solicitation for a vote on the Plan. The Plan will become effective only if it receives the requisite stakeholder approval and if confirmed by the Court. There can be no assurance that the Registrant’s stakeholders will approve the Plan, or that the Court will confirm the Plan.

~~The~~ Immediately ~~Registrant’s~~after ~~management~~the ~~previously informed~~Effective ~~investors~~Date, ~~that~~the itLiquidating ~~had~~Trustee ~~noticed~~shall ~~continuing~~be ~~high~~authorized ~~trading~~to ~~volume~~take ~~in the Registrant’s common stock~~all ~~after~~actions ~~the~~reasonably ~~Registrants’s~~necessary ~~filing~~to ~~for~~dissolve ~~bankruptcy~~Vion ~~and~~under ofapplicable ~~its~~laws; ~~belief~~provided, however, that ~~there~~Vion ~~will~~shall not be nodissolved ~~value~~any ~~for~~sooner ~~the common~~than ~~stockholders in~~ the ~~Registrant’s~~earlier ~~bankruptcy liquidation process, even under the most optimistic~~ of ~~scenarios. Stockholders of~~ (a ~~company in Chapter~~) ~~11 generally receive value only if~~20 months ~~all~~after ~~claims of~~ the ~~company’s~~Effective ~~creditors~~Date ~~are~~or ~~fully~~(b) a ~~satisfied.~~date Inupon ~~this~~which ~~case, the Registrant~~Vion’s ~~management~~ ~~believes~~former ~~all~~employees ~~such~~may ~~claims~~no ~~will~~longer ~~not~~continue ~~be fully satisfied, leading~~ to ~~its conclusion that the~~ ~~Registrant’s~~collect ~~common~~health ~~stock~~benefits ~~will~~under ~~have no value. The Registrant’s management also notes that~~ the ~~Plan,~~Consolidated asOmnibus ~~currently filed,~~Budget ~~provides~~Reconciliation ~~for~~Act ~~no distribution to stockholders and cancellation of all shares but one~~(COBRA).

~~Table~~ Immediately prior to the confirmation of ~~Contents~~the Plan, Vion had 60,000,000 authorized shares of common stock, $0.01 par value per share, of which 8,054,519 were issued and outstanding as of April 5, 2010, and 5,000,000 authorized shares of preferred stock, none of which were issued or outstanding. As a result of the Plan becoming effective, all of Vion’s outstanding shares of common stock will be cancelled without consideration as of the Effective Date and have no value. No shares are being reserved for future issuance in respect of claims and interests filed or allowed under the Plan; provided, however, the Liquidating Trustee will receive and hold one share of the common stock for the purpose of maintaining Vion’s corporate existence pending dissolution. Therefore all of the existing equity interests, including common stock, of Vion are worthless, and there is no value to the conversion rights of Vion’s convertible debt.

~~Item 9.01~~Assets ~~Financial Statements~~ and ~~Exhibits.~~Liabilities

~~(d)~~ In its most recent monthly operating report filed with the Court on March ~~Exhibits~~22, 2010, Vion reported assets of $13,808,535 and liabilities of $66,563,236 as of February 28, 2010.

EXHIBIT NO.				DESCRIPTION
	99.1			Vion Pharmaceuticals, Inc. Monthly Operating Report filed with the United States Bankruptcy Court for the District of Delaware.

Item 3.03 Material Modification to the Rights of Security Holders

~~Table~~ Pursuant to the Plan, all outstanding equity interests of ~~Contents~~Vion, including but not limited to all outstanding shares of common stock, options, warrants or contractual or other rights to acquire any equity interests, are cancelled and extinguished on the Effective Date.

~~Limitation~~ In addition, on ~~Incorporation~~April by8, ~~Reference~~2009, the Company filed a cease trading request with the Financial Industry Regulatory Authority. Accordingly, Vion’s common stock will cease trading and be removed from the OTC quotation systems list.

~~The~~ After ~~Monthly~~filing ~~Operating~~this Current Report ~~shall~~on ~~not~~Form be8-K, ~~deemed~~Vion ~~“filed”~~will ~~for~~file ~~purposes~~a ~~of Section~~Form 1815 ofwith the Securities and Exchange ~~Act~~Commission ofto ~~1934,~~deregister asits ~~amended~~common ~~(the~~stock ~~“Exchange~~under ~~Act”~~Section 12(g), ~~or otherwise subject to the liabilities~~ of ~~that section, nor shall it be deemed incorporated by reference in any filing under~~ the Securities Exchange Act of ~~1933~~1934, as amended, ~~or other documents filed with~~ (the ~~U.S.~~ ~~Securities and~~ “Exchange ~~Commission (“SEC~~Act”). ~~shall~~Vion’s ~~not~~reporting ~~incorporate~~obligations under the ~~Monthly~~Exchange ~~Operating~~Act ~~Report or any other information set forth therein by reference, except as otherwise expressly stated in such filing. This Current Report on Form 8-K~~ will ~~not~~consequently be ~~deemed~~terminated anand ~~admission as to the materiality of any information in the Monthly Operating Report~~suspended.

~~Cautionary~~Item 5.01 ~~Statement~~Changes ~~Regarding~~in ~~Financial~~Control ~~and~~of ~~Operating Data~~Registrant

~~The~~ As ~~Registrant~~of ~~cautions~~the ~~investors~~Effective ~~and~~Date, ~~potential~~following ~~investors~~consummation ~~not~~of ~~to place undue reliance upon~~ the ~~information~~Plan, ~~contained in~~ the ~~Monthly~~Liquidating ~~Operating~~Trustee ~~Report,~~will hold ~~which~~one ~~was~~share ~~not~~of ~~prepared~~Vion ~~for~~common ~~the~~stock ~~purpose~~and ~~of providing~~ the ~~basis~~Vion ~~for~~Liquidating anTrust ~~investment~~will ~~decision~~hold ~~relating~~all ~~to any~~ of the ~~securities~~assets of Vion ~~the~~(excluding ~~Registrant.~~certain ~~The~~licenses ~~Monthly~~and ~~Operating~~drug ~~Report~~applications ~~has~~that ~~been~~are ~~prepared~~being ~~solely~~retained by Vion) for the purpose of ~~complying~~winding ~~with~~down ~~the~~Vion’s ~~monthly reporting~~remaining ~~requirements of, and is in a format acceptable to, the Court~~affairs. ~~The Monthly Operating Report is limited in scope and only covers a limited time period.~~

The Monthly Operating Report was not audited or reviewed by independent accountants and was not prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”)Item 5.02 ~~There~~Departure ~~can be no assurance that, from the perspective~~ of anDirectors ~~investor~~ or ~~a potential~~Certain ~~investor~~Officers; inElection ~~the~~of ~~Registrant’s~~Directors: ~~securities,~~Appointment the Monthly Operating Report is complete. The Monthly Operating Report may be subject to future adjustment and reconciliation. The Monthly Operating Report also contains information for periods which are shorter or otherwise different from those required in the Registrant’s reports pursuant to the Exchange Act, and such information might not be indicative of ~~the Registrant’s financial condition or operating results for the period~~Certain ~~that~~Officers; ~~would~~Compensatory beArrangements ~~reflected in the Registrant’s financial statements or in its reports pursuant to the Exchange Act. The information set forth in the Monthly Operating Report should not be viewed as indicative~~ of ~~future~~Certain ~~results.~~Officers

~~The~~ As ~~Monthly~~of ~~Operating~~the ~~Report~~Effective Date, and ~~additional~~as ~~information~~contemplated ~~about~~by the ~~Registrant~~Plan, Vion’s ~~filings~~Board ~~under~~of ~~the~~Directors will be ~~Bankruptcy~~dissolved ~~Code,~~and ~~including~~its ~~access~~officers towill ~~court~~be ~~documents~~discharged. ~~and~~Accordingly, ~~other~~each ~~general~~of ~~information~~Vion’s ~~about~~directors, ~~the~~William R. ~~Chapter 11~~Miller, ~~Case~~Alan Kessman, ~~are~~George ~~available~~Bickerstaff, ~~online~~Kevin atRakin, ~~the~~Alan ~~Registrant~~C. Sartorelli, Ph.D., Ian Williams, D. Phil and Gary Willis, and each of Vion’s ~~claims~~remaining ~~administration~~officers, ~~website~~Alan ~~located~~Kessman, atHoward B. Johnson, Karen ~~http://www~~Schmedlin, and Dr.~~delclaims~~ Ivan King, will cease to be directors or officers of Vion on the Effective Date.~~com/caseinfo/C09-14429.html.~~

~~Cautionary~~Item 9.01 ~~Statement~~Financial ~~Regarding Forward-Looking~~ Statements and Exhibits

This Current Report on Form 8-K and its exhibits contain forward-looking statements that are subject to certain risks and uncertainties that could cause the Registrant’s plans or actual results to differ materially from those projected, including the Registrant being unsuccessful in selling its assets or engaging in another transaction in bankruptcy, the Registrant not obtaining court approval of its motions in the Chapter(d) ~~11 proceeding, including its motions for approval of~~Exhibits. ~~its plan of liquidation, the Registrant’s ability to develop, pursue, confirm and consummate one or more plans of reorganization with respect to the Chapter 11 case, the~~


EXHIBIT NO.		DESCRIPTION

99.1		Order Confirming Vion Pharmaceuticals, Inc.’s Second Amended Chapter 11 Plan of Liquidation.

~~Registrant’s ability to retain and compensate key executives and other key employees, the~~SIGNATURES Registrant’s ability to maintain relationships with its licensor and vendors, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in the Registrant’s filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, “Risk Factors” in the Registrant’s Form 10-K for the year ended December 31, 2008 and the Registrant’s Form 10-Q for the quarter ended September 30, 2009. The cautionary statements provided above are being made pursuant to and with the intention of obtaining the benefits of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 to the extent available to the Registrant for any such forward-looking statements. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, the Registrant does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

~~Table~~ Pursuant to the requirements of ~~Contents~~the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGNATURES


	VION PHARMACEUTICALS, INC.
Date: April 8, 2010	By:	/s/ Howard B. Johnson
		Name:	Howard B. Johnson
		Title:	President and Chief Financial Officer

~~Pursuant~~EXHIBIT ~~to the requirements of the Securities Exchange Act of 1934, the registrant has duly~~INDEX ~~caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~

	VION PHARMACEUTICALS, INC.
EXHIBIT NO.		DESCRIPTION
Date: March 23, 2010	By:	/s/ Howard B. Johnson
99.1		Order Confirming Vion Pharmaceuticals, Inc.’s Second Amended Chapter II Plan of Liquidation.
		Name:	Howard B. Johnson
		Title:	President and Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO.				DESCRIPTION
	99.1			Vion Pharmaceuticals, Inc. Monthly Operating Report filed with the United States Bankruptcy Court for the District of Delaware.

Table of Contents

Table of Contents

Filing Compare · VION PHARMACEUTICALS INC